GlassScriptPhysician profile
Tammy Eileen Castro
NPI 1164665972
$9,190.20
in general payments reported to CMS, 2019-2025
29 companies · $2,846 in 2025
The $2,846 reported for 2025 was more than what 97% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,055 · 2023: $2,278 · 2024: $3,010 · 2025: $2,846.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,985 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $150.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,984.77 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $150.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,561.14 | 2022-2025 | |
| Neurocrine Biosciences, INC. | $743.80 | 2022-2025 | Ingrezza |
| Boston Scientific Corporation | $511.82 | 2022-2025 | Watchman Access System, Watchman Flx |
| Abiomed | $504.78 | 2024-2025 | Impella |
| Amgen INC. | $492.89 | 2022-2025 | Krystexxa |
| Dexcom, INC. | $475.79 | 2023-2025 | Dexcom G7 Gss (161), Dexcom Stelo Glucose Biosensor |
| Abbott Laboratories | $463.41 | 2023-2024 | Freestyle Libre 3, Cardiomems, Mitraclip |
| Actelion Pharmaceuticals US, INC. | $446.10 | 2023-2024 | Uptravi, Opsumit |
| Novo Nordisk INC | $431.82 | 2022-2025 | Wegovy |
| Corcept Therapeutics | $340.13 | 2024-2025 | Korlym |
| Genzyme Corporation | $323.54 | 2023-2025 | |
| Insmed, INC. | $300.01 | 2024-2025 | Arikayce |
| Astrazeneca Pharmaceuticals LP | $287.96 | 2022-2025 | Airsupra, Lokelma |
| Otsuka America Pharmaceutical, INC. | $246.08 | 2023-2024 | Rexulti |
| Arcutis Biotherapeutics, INC. | $241.01 | 2023-2024 | Zoryve |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $235.48 | 2023-2024 | |
| Sanofi-Aventis U.S. LLC | $235.43 | 2024-2025 | |
| Sanofi Pasteur INC. | $168.94 | 2023-2025 | |
| Cvrx, INC. | $137.80 | 2025 | Barostim Neo System |
| Teva Pharmaceuticals USA, INC. | $133.36 | 2025 | Austedo Xr |
| E.R. Squibb & Sons, L.L.C. | $127.62 | 2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $121.84 | 2024 | Xifaxan |
| Axonics, INC. | $118.04 | 2024 | Axonics, Bulkamid |
| Lilly USA, LLC | $112.19 | 2022 | |
| Idorsia Pharmaceuticals US INC | $103.22 | 2023 | Quviviq |
| Gilead Sciences, INC. | $102.66 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $101.18 | 2024 | Jardiance |
| Lucid Diagnostics INC. | $100.43 | 2023 | |
| Merck Sharp & Dohme LLC | $21.73 | 2024 | Pifeltro, Delstrigo |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Tammy Castro listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.